Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

Abbott received a breakthrough device designation from the US Food and Drug Administration (FDA) to investigate the use of ...

Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it looks to prioritise its portfolio of weight loss drug implants. While Vivani ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

neuromodulation, structural heart, heart failure, rhythm management, and diabetes care. Several growth potentials are highlighted by Abbott Laboratories (NYSE:ABT)’s primary business.

Morningstar brands and products Company Portfolio ...

A team of experts from the Icahn School of Medicine at Mount Sinai has become the first in the United States to perform a ...

The Vietnam baby food products market is projected to experience a steady growth rate, with a CAGR of 1.53% during the forecast period from 2025 to 2032. The market, valued at $1303.60 million in 2024 ...